Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim

Allogene Therapeutics, Inc.

58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.
No CRS, ICANS, or GvHD reported; 10 of 12 cema-cel patients managed fully outpatient.
Plasma ctDNA decreased 97.7% median in cema-cel arm vs 26.6% increase in observation at Day 45.
Cema-cel arm had more aggressive disease (100% stage III-IV, 41.7% IPI 4-5) than observation.
ALPHA3 targets ~220 patients; enrollment complete by end 2027; interim EFS mid-2027, primary mid-2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.